Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App





New 1-Minute COVID-19 Antibody Test Uses Innovative Flow-Through Technology to Deliver Results

By LabMedica International staff writers
Posted on 16 Oct 2020
A new one-minute antibody test for COVID-19 launched in Europe is the only test of its kind to use innovative flow-through technology to deliver results, making it far faster than other antibody tests currently available.

bioLytical Laboratories (Vancouver, BC, Canada) has launched INSTI COVID-19 Antibody Test, its new one-minute test that detects antibodies to SARS-CoV-2 with high accuracy, in Europe following the notification of CE mark and approval to sell the test across the region. More...
The test detects total antibodies to SARS-CoV-2 and is the only one of its kind to use innovative flow-through technology to deliver results, making it far faster than other antibody tests currently available. The INSTI COVID-19 Antibody Test is completely portable, does not require additional equipment and can be performed in a multitude of settings with easy-to-interpret results. Test providers have the advantage of running more tests in less time, due to INSTI's market-leading speed.

“Reliable and truly rapid antibody tests are an important part of our response to this global crisis,” said Robert Mackie, Chief Executive Officer. “The INSTI COVID-19 Antibody Test is a uniquely effective tool and distribution of our one-minute test kits around the globe is a critical step for tackling the spread of this virus.”

Related Links:
bioLytical Laboratories


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.